Exclusion Criteria:~* Taken memantine within 2 months prior to screening.~* Current diagnosis of any
psychiatric disorder, depression that is not well-controlled, clinically significant or unstable systemic
disease, or severe medical procedures~* Clinically relevant abnormal laboratory values suggesting an unknown
disease and requiring further clinical evaluation.~* Patients at imminent risk of self-harm, based on clinical
interview and response on S-STS~* History of malignancy occurring within 5 years immediately prior to
screening, except for a subject who has been adequately treated for (1) basal cell or squamous cell skin
cancer, (2) in situ cervical cancer, (3) localized prostate carcinoma, or (4) who has undergone potentially
curative therapy with no evidence of recurrence for more than 3 years post-therapy, and who is deemed at low
risk for recurrence by her/his treating physician~* History of any of the following cardiovascular conditions
that an unstable:~ * Hypotension~ * Hypertension~ * Active cardiovascular disease~* Evidence of cerebrovascular
disease~* Have used or plan to use the following medications from 30 days prior to Visit 1 through the end of
the study:~ * Narcotic analgesics more frequently than on three days per week as needed for pain;~ * Daily
antipsychotic (except for risperidone, quetiapine and aripiprazole, and only if at a stable and controlled
dose)~ * Daily anxiolytic use; however, occasional use as needed for acute agitation or to be used as a rescue
anxiolytic (i.e., lorazepam and oxazepam) is acceptable as long as not used within 24 hours of a clinic visit
window;~ * Daily antidepressants (except for citalopram, escitalopram, venlafaxine, trazodone, sertraline, and
mirtazapine, and only if at a stable and controlled dose);~ * Low potency antipsychotic agents (eg
chlorpromazine) - not permitted at any time during the study;~ * Anti-parkinson's disease medications
(selegiline, levodopa, amantadine) for the treatment of Parkinson's Syndrome Complex;~ * Lithium;~ *
Clozapine;~* Previously treated with or currently using montelukast
